Trial Profile

A Prospective, Single-arm, Single-center, Phase II Clinical Study of Triple-negative Breast Cancer Brain Metastases

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adebrelimab (Primary) ; Bevacizumab (Primary) ; Carboplatin; Cisplatin
Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; Triple negative breast cancer
Focus Therapeutic Use

18 Jul 2024 Protocol of this study has been amended as design term Parallel drugs pyrotinib and temozolomide has been removed, hence number of treatment arms has been changed to 1 from 2, patients with Her-2 positive breast cancer are not being recruited instead patients with Her-2 negative breast cancer are being recruited in this study and planned number of patients changed from 59 to 35.
18 Jul 2024 Planned End Date changed from 30 Jan 2022 to 30 May 2025.
18 Jul 2024 Planned primary completion date changed from 30 Dec 2021 to 30 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com